Taking Nominations

Taking Nominations

It’s been quite some time since Diabetic Investor held an awards show and with the Oscars just a few short weeks away we thought now is as good a time as any.  As with past awards, our personal favorites being The Corporate Frog Awards and The Wacky Wabbitt Awards, the theme this year will be The Wacky World Awards. Yes diabetes is a global business so it would be provincial even snobby if we excluded the many fine companies and individual located beyond our shores.

Just to keep things interesting we will NOT accept any nominations for our wine drinking friends in France as quite honestly giving the soap opera known as Sanofi (NYSE:SNY) a Wacky World is a no brainer. Nor will accept any nominations for their acting CEO foot in mouth specialist Serge Weinberg even though no other CEO is more deserving. Additionally we will extend this ban to include their Ex-CEO and many ex-executives, some of whom who just might end up in jail.  Honestly it would be unfair to the many deserving companies and individuals if Sanofi was allowed to participate. However given how deserving the company and its diabetes management team is we have created a special award just for Sanofi- the Exubera – as like Pfizer (NYSE:PFE) before them they too are about to blow a ton of money on a product that has limited appeal, disastrous formulary position which has been placed in the hands of a sales team that has been publicly humiliated.

We also want to award the Welcome to Wacky to Pat Sullivan, the new CEO if Insulet (NASDAQ:PODD). Frankly we can’t think of anyone more deserving given the pile of manure he stepped into. Nothing like finding out that the previous management team was less than honest in their public comments. Yes it appears the inmates were running the asylum and now it’s up to Mr. Sullivan to clean up one huge mess. Good luck Pat and Welcome to the Wacky World.

On the flip side  the Terry Gregg Management award – given to the best managed diabetes company – goes to …….Dexcom (NASDAQ:DXCM). As we stated on numerous occasions Dexcom is setting the standard when it comes to knowing how to run a diabetes company. It’s fitting that that the very first Gregg goes to the company he once ran and left in very capable hands.

Flipping back – the major branded glucose monitoring companies – Johnson and Johnson (NYSE:JNJ), Roche, Abbott (NYSE:ABT) and Bayer (yes Bayer is still in the business for how long we’re not sure but until someone comes along and is stupid enough to plunk down a billion bucks or so it’s appropriate that Bayer share in this honor) all will share the Turn Out The Lights The Party is Over award.  Yes after years of making truly obscene margins, margins that would make a Chicago loan shark blush, the party is over. All we ask is whoever is still here 5 years from now, are you listening JNJ, please turn off the lights and close the door.

The Comeback Award goes to our good friends in Indianapolis (sorry about the deflated balls but honestly that’s not the reason the Colts got trashed by the cheater Patriots) Eli Lilly (NYSE:LLY). As we have stated many times we’re not sure their diabetes strategy will work but one thing is certain this strategy already has everyone else in diabetes drugs scrambling. Welcome back to the wacky world and don’t worry the Colts have a great quarterback and it’s just a matter of time before they get back to the big game.

Perhaps the most difficult category of all is the Newcomer to Wackiness Award as there are so many deserving nominees. Google and their contact lenses that measure glucose levels is worthy. As is Apple, Samsung, Panasonic, Facebook and just about every tech company located near that beautiful city by the bay. Yes this group of well-known high powered cash rich companies are now hip deep in diabetes. Therefore we will give the award to every company who believes that interconnected diabetes management (IDM) as powerful of a tool as it COULD be, will actually become the standard of care anytime soon. The only special request we have is to be able to sit in when they meet with the FDA and we promise we won’t burst out laughing when the agency makes a crazy request that makes absolutely no sense whatsoever.

Now we’re sure we have left out many deserving companies and individuals so it’s up to you the loyal readers of Diabetic Investor. The floor is open for nominations.